{"filings":[{"id":695916,"accession_number":"0001193125-26-241922","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2026-05-27T20:16:22+00:00","items":["5.07"],"status":"ready","headline":"Nuvation Bio stockholders elect directors, ratify KPMG, approve say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class A directors Robert B. Bazemore Jr. and Robert Mashal elected with 197.7M and 216.8M votes for, respectively.","Class B director Kim Blickenstaff elected with 1,000,000 votes for (no withhold).","Ratification of KPMG as independent auditor for FY 2026 approved with 290.3M votes for.","Advisory say-on-pay resolution passed with 230.1M votes for, 5.0M against, and 55.6M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95665,"accession_number":"0001193125-26-204056","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q1 2026 net product revenue $18.5M; net income $5.4M vs loss year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $18.5M from IBTROZI; net income $5.4M ($0.02 basic EPS) vs net loss $53.2M year ago.","Collaboration revenue $64.7M including $58.7M upfront from Eisai; cash and securities $533.7M.","Over 600 patients started IBTROZI since launch; majority of ~200 new Q1 patients were TKI-naïve.","Acquired Japan rights to safusidenib from Daiichi Sankyo, gaining full global development and commercialization rights.","Updated pooled TRUST data at AACR: mPFS 46.1 months, mDOR 49.7 months in TKI-naïve ROS1+ NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":83228000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108889,"accession_number":"0001193125-26-085474","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Reports Q4 2025 Revenue of $15.7M, 216 New IBTROZI Patient Starts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IBTROZI (taletrectinib) launched in June 2025; 432 new patient starts by end of Q4 2025, with 216 in Q4 alone.","Entered exclusive licensing/collaboration with Eisai on Jan 11, 2026 for taletrectinib in Europe and other regions.","Cash, equivalents, and marketable securities of $529.2M as of Dec 31, 2025.","Net product revenue from IBTROZI: $15.7M in Q4 2025, $24.7M for full year 2025.","Positive Phase 2 safusidenib results published; ORR 44%, 88% progression-free at 24 months in grade 2 IDH1-mutant glioma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108888,"accession_number":"0001193125-26-009826","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Nuvation Bio licenses taletrectinib to Eisai for up to €195M; Q4 IBTROZI rev $15.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license to Eisai for taletrectinib in EU, Canada, Australia, Middle East, India, others; upfront €50M, up to €145M milestones, royalties up to high-teens.","Preliminary Q4 IBTROZI net revenue $15.7M; total $24.7M since June 2025 launch; 432 new patient starts.","Preliminary cash $529.2M at Dec 31, 2025; received $25M milestone from Nippon Kayaku.","MAA for taletrectinib in Europe expected H1 2026; first €25M milestone upon EU approval.","Company continues enrollment of safusidenib phase 3 study in IDH1-mutant gliomas; full FY2025 results due March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125347,"accession_number":"0001193125-25-298551","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nuvation Bio discontinues NUV-1511 DDC program; redirects $100-150M to pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued NUV-1511 due to inconsistent efficacy across cohorts; DDC platform continues.","Projected $100-150M in R&D/CMC costs through 2029 reallocated to other pipeline molecules.","First patient enrolled in part 2 of G203 study of safusidenib for IDH1-mutant glioma.","Continued investment in IBTROZI (taletrectinib) commercial launch and TRUST-IV adjuvant study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125346,"accession_number":"0001193125-25-284845","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nuvation Bio reports Phase 2 ORR 44.4% for safusidenib in IDH1-mutant gliomas","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Safusidenib met primary endpoint with 44.4% objective response rate in 27 Japanese patients with grade 2 IDH1-mutant gliomas.","Median PFS not reached at median 28 months follow-up; 87.9% progression-free at 24 months.","Grade 3+ treatment-related adverse events in 18.5% of patients; no grade 5 events; GCP noncompliance on safety reporting resolved via re-collection.","Company progressing G203 global Phase 3 study for high-risk IDH1-mutant glioma; FDA agreed PFS by BICR per RANO 2.0 could support full approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125345,"accession_number":"0001193125-25-262576","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q3 net loss widens to $55.8M; first IBTROZI revenue $7.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $55.8M ($0.16 loss per share) vs. $41.2M ($0.15) in Q3 2024.","Net product revenue from IBTROZI $7.7M; collaboration revenue $5.4M (up from $0.7M).","204 new patients started IBTROZI in Q3; median duration of response matured to 50 months.","Cash, cash equivalents, and marketable securities $549.0M at Sept 30, 2025.","First patients enrolled in TRUST-IV adjuvant study and safusidenib G203 study."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":21037000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142060,"accession_number":"0001193125-25-174954","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q2 net loss $59M; IBTROZI launch with 70 patients in 7 weeks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA approved IBTROZI (taletrectinib) for ROS1+ NSCLC on June 11; 70 patients started by July 31.","Cash, equivalents and marketable securities $607.7M; received $200M non-dilutive financing from Sagard.","Product revenue net $1.2M from IBTROZI for 13 days of sales; collaboration revenue $3.6M (up from $1.4M).","Net loss $59M ($0.17/sh) vs $462.5M ($1.89) in prior year which included AnHeart acquisition cost.","NCCN guidelines added taletrectinib as preferred agent across lines of therapy for ROS1+ NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":7917000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160035,"accession_number":"0001193125-25-139164","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nuvation Bio announces FDA approval of IBTROZI (taletrectinib) for ROS1+ NSCLC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved IBTROZI for adult patients with locally advanced or metastatic ROS1+ NSCLC.","In TRUST-I, cORR of 90% in TKI-naïve patients; TRUST-II cORR of 85%; median DOR not yet reached.","Intracranial response in 73% of TKI-naïve and 63% of TKI-pretreated patients with brain metastases.","Generally well-tolerated; 7% discontinued due to TEAEs; most common AEs: diarrhea (64%), nausea (47%), vomiting (43%).","Approved dose 600 mg once-daily; half-life ~66 hours enabling sustained CNS exposure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160034,"accession_number":"0001193125-25-125763","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nuvation Bio stockholders elect directors, ratify auditor, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three proposals passed at May 21, 2025 annual meeting; quorum of 82.8% of Class A shares present.","Kathryn E. Falberg elected Class A director with 198.6M for, 18.0M withheld; David Hung elected Class B director with 1.0M for.","Ratification of KPMG LLP as auditor for FY2025: 279.9M for, 1.6M against, 15.8K abstain.","Advisory approval of named executive officer compensation: 214.9M for, 1.6M against, 143.8K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160033,"accession_number":"0001193125-25-114908","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q1 net loss $53.2M; cash $461.7M; taletrectinib PDUFA June 23, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $53.2M ($0.16/share) vs $14.8M ($0.07) in Q1 2024; R&D rose to $24.6M, SG&A to $35.4M.","Cash, equivalents and marketable securities $461.7M as of March 31, 2025.","FDA Priority Review for taletrectinib NDA on track; PDUFA goal date June 23, 2025.","Secured up to $250M non-dilutive financing from Sagard Healthcare; $150M royalty and $50M debt upon FDA approval.","Appointed Stephen Dang, Ph.D., as Senior Vice President, General Counsel in March 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":3084000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178369,"accession_number":"0001193125-25-062031","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Nuvation Bio enters commercial supply agreement with Asymchem for taletrectinib drug product","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Asymchem will be non-exclusive supplier of taletrectinib drug product; Nuvation retains right to use alternate manufacturers.","Orders must be placed at least 180 days before delivery; cancellation subject to tiered fees.","Initial term is 5 years, auto-renews for consecutive 3-year terms unless non-renewed.","Company may terminate without cause on 30 days' notice; each party may terminate for material breach or insolvency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178368,"accession_number":"0001193125-25-048529","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio: taletrectinib NDA Priority Review, $250M financing, Q4 net loss $49.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA accepted NDA for taletrectinib with Priority Review; PDUFA goal date June 23, 2025 for advanced ROS1+ NSCLC.","Secured up to $250M non-dilutive financings from Sagard: $150M royalty interest plus $50M debt upon FDA approval.","Q4 net loss $49.4M ($0.15/sh) vs $13.8M ($0.06) in Q4 2023; R&D and SG&A rose due to AnHeart acquisition.","China NMPA approved taletrectinib Jan 2025 (Innovent commercializing); Nippon Kayaku submitted MAA in Japan.","Launched U.S. Expanded Access Program for taletrectinib in February 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178367,"accession_number":"0001193125-25-047165","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Nuvation Bio enters 5-year supply agreement with Asymchem for taletrectinib drug substance","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Asymchem will be a non-exclusive supplier; Nuvation retains right to use alternate manufacturers.","Initial term of 5 years, auto-renews for 3-year periods unless either party gives 6-month nonrenewal notice.","Orders must be placed at least 180 days before delivery; cancellations incur tiered percentage fees.","Company may terminate without cause on 30 days' notice; either party may terminate for material breach or insolvency.","Agreement covers delivery, quality, IP, confidentiality, and indemnification; financial terms not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178366,"accession_number":"0001193125-25-045568","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Nuvation Bio secures up to $250M in debt and royalty financing for taletrectinib","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$100M loan with Sagard; initial $50M tranche upon FDA approval of taletrectinib by Sep 30, 2025; second $50M upon first US commercial sale by Jun 30, 2026","Loan matures Sep 30, 2030, interest SOFR (4% floor) + 6% quarterly; prepayment premiums; $25M minimum cash covenant","$150M revenue interest financing; tiered royalties: 5.5% on US net sales up to $600M, 3.0% on $600M-$1B, none above $1B","Royalty obligation ends at 1.6x-2.0x investment amount; true-up if not repaid by Feb 1, 2043","Company can buy out royalty at 140%-200% of investment amount less payments made; investor can put upon certain events"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178365,"accession_number":"0001193125-25-025099","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dr. Jerry Wang exits AnHeart Therapeutics CEO role after taletrectinib milestones achieved","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Wang departed as CEO of AnHeart Therapeutics, a Nuvation Bio subsidiary, on Feb. 12, 2025.","Departure follows China NMPA approval of taletrectinib for advanced ROS1-positive NSCLC.","Also follows FDA acceptance and priority review of NDA for taletrectinib in advanced ROS1-positive NSCLC.","Dr. Wang resigned from Nuvation Bio board effective Feb. 11, 2025; no disagreement with company.","Role eliminated as redundant after successful integration of AnHeart Therapeutics post-merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195020,"accession_number":"0001193125-24-252153","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio reports Q3 net loss of $41.2M, submits NDA for taletrectinib in ROS1+ NSCLC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $41.2M ($0.15 per share) vs $19.6M ($0.09) in Q3 2023; cash of $549.1M at Sept 30.","NDA for taletrectinib submitted to FDA for line-agnostic full approval in advanced ROS1+ NSCLC; potential launch mid-2025.","Pooled Phase 2 data: 89% ORR in TKI-naïve patients, median DOR 44 months and PFS 46 months; low 7% discontinuation rate.","Appointed Philippe Sauvage as CFO in October; David Hung appointed Chairman, Robert Bazemore lead independent director.","R&D expenses $27.7M (up $9.2M YoY); G&A $19.6M (up $11.8M YoY) driven by AnHeart acquisition costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":2162000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195019,"accession_number":"0001193125-24-233794","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nuvation Bio appoints Philippe Sauvage as CFO effective October 7, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Philippe Sauvage appointed CFO; previously SVP Global Head of Operations & Access at Sanofi (2020-2024).","Initial annual base salary of $510,000; annual discretionary bonus up to 45% of base.","Option award for 750,000 shares; vests 1/4 on one-year anniversary, then monthly vesting.","Severance: 12 months base salary plus COBRA reimbursement; change-in-control double trigger with full equity acceleration.","No family relationships or material transactions with directors or officers disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211310,"accession_number":"0001193125-24-214241","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Nuvation Bio shareholders approve 85M share conversion; CEO Hung named Board Chair","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved conversion of Series A Preferred into up to 85,120,200 Class A shares; conversion completed Sept 4, resulting in 333.8M Class A shares outstanding.","CEO David Hung appointed Chair of the Board; Robert Bazemore appointed Lead Independent Director.","Committee chairs set: Falberg (Audit), Vernon (Compensation), Bazemore (Nominating/Governance).","All five proposals passed: directors elected, KPMG ratified, executive compensation approved, conversion approved, adjournment approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211309,"accession_number":"0001193125-24-193412","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q2 net loss $462.5M on $425.1M AnHeart charge; halts NUV-868 Phase 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $462.5M ($1.89/share) vs. $20.6M ($0.09) Q2 2023; includes $425.1M acquired IPR&D charge from AnHeart acquisition.","Cash, equivalents, and marketable securities of $577.2M as of June 30, 2024.","R&D expenses $29.2M (up 57% YoY) and G&A $16.1M (up 115% YoY) partly due to AnHeart.","Decided not to initiate Phase 2 for NUV-868 in prior solid tumor indications; evaluating next steps.","Taletrectinib NDA planned in U.S. in 2025 based on pooled TRUST-I/II data at ESMO 2024; received FDA Orphan Drug Designation."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":1435000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229878,"accession_number":"0001193125-24-164595","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K/A","filed_at":"2024-06-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuvation Bio files 8-K/A with AnHeart financials and updated taletrectinib clinical data","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Acquired AnHeart in Apr 2024; audited AnHeart FY2023 and FY2022 financials included.","Taletrectinib TRUST-I: 90.6% cORR in TKI-naive ROS1+ NSCLC; median PFS not reached at 23.5 mo f/u.","Intracranial cORR 87.5% (TKI-naive) and 73.3% (TKI-pretreated) in TRUST-I; low neuro TEAEs.","NDA accepted in China with priority review for taletrectinib; Breakthrough Therapy in US and China.","Innovent out-license: $55M received; up to $29M regulatory + $105M commercial milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229880,"accession_number":"0001193125-24-138263","cik":1811063,"company_name":"Nuvation Bio Inc.","ticker":"NUVB","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvation Bio Q1 net loss $14.8M; completes AnHeart acquisition; cash $597M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.8M ($0.07 per share) vs $21.7M ($0.10) in Q1 2023.","Cash, equivalents and marketable securities of $597.0M as of March 31, 2024.","Acquisition of AnHeart Therapeutics closed in April 2024, transforming Nuvation into late-stage global oncology company.","Appointed Colleen Sjogren as Chief Commercial Officer; first patient dosed in Phase 1/2 study of NUV-1511 DDC.","Updated taletrectinib Phase 2 TRUST-I data to be presented at ASCO 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1639503148.3164556,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}